C
Chloe Orkin
Researcher at Queen Mary University of London
Publications - 229
Citations - 14129
Chloe Orkin is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 11614 citations. Previous affiliations of Chloe Orkin include Barts Health NHS Trust & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
Lars Peters,Amanda Mocroft,Daniel Grint,Santiago Moreno,Alexandra Calmy,Djordje Jevtovic,Helen Sambatakou,Karine Lacombe,Stéphane De Wit,Jürgen K. Rockstroh,Jelena Smidt,Igor Karpov,Anna Grzeszczuk,Vesnadarjan Haziosmanovic,Magnus Gottfredsson,Roxana Radoi,Elena Kuzovatova,Chloe Orkin,Anna Lisa Ridolfo,Jose Zapirain,Jens D Lundgren +20 more
TL;DR: Although use of tenofovir-based cART among HIV-HBV patients has increased across Europe, a substantial proportion are still starting cART late and are receiving suboptimal HBV therapy.
Journal ArticleDOI
Two-drug regimens for HIV treatment.
Kevin M Gibas,Sean G. Kelly,Jose R. Arribas,Pedro Cahn,Chloe Orkin,Eric S. Daar,Paul E. Sax,Babafemi Taiwo +7 more
TL;DR: Two-drug combinations are now recommended in treatment guidelines and include the first long-acting antiretroviral regimen for the treatment of HIV-1 as discussed by the authors , which is the first two-drug regimen for individualised care.
Journal ArticleDOI
THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection
Marianne Martinello,Chloe Orkin,Graham S Cooke,Sanjay Bhagani,Edward Gane,Ranjababu Kulasegaram,David R. Shaw,Elise Tu,Ecaterina Filep,Kathy Petoumenos,P. Marks,Tanya L. Applegate,Jason Grebely,Gregory J. Dore,Mark T. Nelson,Gail V. Matthews +15 more
Journal ArticleDOI
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate
Muge Cevik,Chloe Orkin +1 more
TL;DR: D/C/F/TAF FDC demonstrated excellent, noninferior virological efficacy, maintained a high genetic barrier and conferred the additional safety benefits of TAF, and offers a new option for the treatment of HIV infection.
Journal ArticleDOI
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Collins Iwuji,Collins Iwuji,Duncan Churchill,Stephen Bremner,Nicky Perry,Ye To,Debbie Lambert,Chloe Bruce,Laura Waters,Chloe Orkin,Chloe Orkin,Anna Maria Geretti +11 more
TL;DR: Preliminary evidence of the efficacy of switching to B/F/TAF in patients with virological suppression on a bPI-based regimen who harbour select drug resistance mutations is provided.